Cover Image
市場調查報告書

口乾症:開發中產品分析

Xerostomia - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 245972
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
口乾症:開發中產品分析 Xerostomia - Pipeline Review, H1 2015
出版日期: 2015年01月30日 內容資訊: 英文 41 Pages
簡介

口乾症指的是口腔異常乾燥的狀態。症狀有口腔或喉嚨乾燥、口臭、咀嚼、會話、吞嚥困難、義齒安裝問題、頻繁地蛀牙等。致病因素有老化,癌症治療,神經損傷等。

本報告提供口乾症的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

口乾症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Acacia Pharma Ltd.
  • Hadasit Medical Research Services & Development Ltd
  • Kadmon Corporation, LLC
  • Parion Sciences, Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • APD-515
  • Gene Therapy to Activate Aquaporin-1 for Xerostomia
  • Gene Therapy to Activate Aquaporin-1 for Xerostomia
  • HYPER-IL-6
  • P-552

開發中產品的最新趨勢

暫停開發的計劃

產品開發的里程碑

  • 關注的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6223IDB

Summary

Global Markets Direct's, 'Xerostomia - Pipeline Review, H1 2015', provides an overview of the Xerostomia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Xerostomia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Xerostomia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Xerostomia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Xerostomia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Xerostomia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Xerostomia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Xerostomia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Xerostomia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Xerostomia Overview
  • Therapeutics Development
    • Pipeline Products for Xerostomia - Overview
    • Pipeline Products for Xerostomia - Comparative Analysis
  • Xerostomia - Therapeutics under Development by Companies
  • Xerostomia - Therapeutics under Investigation by Universities/Institutes
  • Xerostomia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Xerostomia - Products under Development by Companies
  • Xerostomia - Products under Investigation by Universities/Institutes
  • Xerostomia - Companies Involved in Therapeutics Development
    • Acacia Pharma Ltd.
    • Hadasit Medical Research Services & Development Ltd
    • Kadmon Corporation, LLC
    • Parion Sciences, Inc.
  • Xerostomia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • APD-515 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Aquaporin-1 for Xerostomia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Aquaporin-1 for Xerostomia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HYPER-IL-6 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-552 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Xerostomia - Recent Pipeline Updates
  • Xerostomia - Dormant Projects
  • Xerostomia - Product Development Milestones
    • Featured News & Press Releases
      • Oct 15, 2013: Acacia Pharma Announces Positive Phase II Results With APD515 for Xerostomia in Advanced Cancer
      • Jul 25, 2011: Acacia Pharma Initiates Phase II Clinical Trial With APD515 For Xerostomia
      • Feb 07, 2011: Acacia Pharma Completes Phase I Clinical Trial With APD515 For Xerostomia
      • Jan 06, 2011: Acacia Pharma Starts Clinical Trial With APD515 In Xerostomia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Xerostomia, H1 2015
  • Number of Products under Development for Xerostomia - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Number of Products under Investigation by Universities/Institutes, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Products under Investigation by Universities/Institutes, H1 2015
  • Xerostomia - Pipeline by Acacia Pharma Ltd., H1 2015
  • Xerostomia - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015
  • Xerostomia - Pipeline by Kadmon Corporation, LLC, H1 2015
  • Xerostomia - Pipeline by Parion Sciences, Inc., H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Xerostomia Therapeutics - Recent Pipeline Updates, H1 2015
  • Xerostomia - Dormant Projects, H1 2015

List of Figures

  • Number of Products under Development for Xerostomia, H1 2015
  • Number of Products under Development for Xerostomia - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top